Roche and Blueprint Medicines Partner Again in US$1.7 B Pralsetinib Pact

By Neha Madhwani & Michelle Liu

Pharma Deals Review: Vol 2020 Issue 7 (Table of Contents)

Published: 31 Jul-2020

DOI: 10.3833/pdr.v2020.i7.2553     ISSN: 1756-7874

Section: Licensing



Blueprint Medicines has entered into a global licensing and collaboration agreement with Roche to develop and commercialise pralsetinib for the treatment of RET-altered cancers...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details